NAMPT and cancer: This evidence suggests that the stromal activation promoted by NAD+ inhibition could limit the efficacy of anti-cancer therapies targeting NAD+ biosynthesis, such as NAMPT inhibitors, and could explain their reported limited efficacy in vivo (Galli et al., 2020).